Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
Geen effecten gevonden.

Nieuws over “Biotechnologie”

29/08 · IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT · Persbericht

29/08 · IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT · Persbericht

29/08 · FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease · Persbericht

29/08 · FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease · Persbericht

29/08 · AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE · Persbericht

29/08 · IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress · Persbericht

29/08 · Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL · Persbericht

29/08 · Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR · Persbericht

29/08 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

29/08 · OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM · Persbericht

29/08 · REPL Class Action Reminder: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Replimune Group, Inc. Class Action Lawsuit · Persbericht

28/08 · Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences · Persbericht

28/08 · Viking Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

28/08 · FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone · Persbericht

28/08 · Halozyme to Participate at Upcoming Investor Conferences · Persbericht

28/08 · Oncolytics Biotech® Announces Upcoming Investor Conferences in September · Persbericht

28/08 · REGENXBIO to Participate in Upcoming Investor Conferences · Persbericht

28/08 · Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference · Persbericht

28/08 · Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera · Persbericht

28/08 · Tilray Medical Expands Presence in Germany with Introduction of New Good Supply Medical Cannabis Strains · Persbericht

28/08 · Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York · Persbericht

Mijn selecties